Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2012 2
2013 1
2016 1
2022 1
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Educational and Socioeconomic Correlates of Stroke Risk Behaviors: Findings from the SPRINT INDIA Trial.
Verma SJ, Kaur G, Devi A, Arora D, Dhasan A, Sylaja PN, Khurana D, Pamidimukkala V, Ray BK, Nambiar V, Aaron S, Mittal G, Nagarjunakonda S, Pai AR, Gorthi SP, Kumaravelu S, Reddy YM, Narayan S, Borah NC, Das R, Kulkarni GB, Huded V, Mathew T, Srivastava MP, Bhatia R, Ojha PK, Roy J, Abraham SM, Vaishnav AG, Sharma A, Jabeen S, Pathak A, Bhoi SK, Sharma S, Sulena S, Saroja AO, Ramrakhiani N, Kempegowda MB, Kate M, George T, Sebastian I, Sharma M, Dhaliwal R, Huilgol R, Pandian JD. Verma SJ, et al. Among authors: vaishnav ag. Ann Indian Acad Neurol. 2025 May 19. doi: 10.4103/aian.aian_933_24. Online ahead of print. Ann Indian Acad Neurol. 2025. PMID: 40387006 Free article.
Neurologic safety event rates in the SENTIS trial control population.
Lutsep HL, Altafullah IM, Roberts R, Silverman IE, Turco MA, Vaishnav AG. Lutsep HL, et al. Among authors: vaishnav ag. Acta Neurol Scand. 2013 Feb;127(2):e5-7. doi: 10.1111/ane.12005. Epub 2012 Sep 18. Acta Neurol Scand. 2013. PMID: 22988905 Clinical Trial.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.